Medical Devices: Reducing Time to Get New Products in the Market

The U.S. Food and Drug Administration (FDA) has increased the data requirements for and become more difficult regarding medical device clearance and approvals, resulting in delays for new devices, unnecessary costs to the health care system, and restricted capital for promising new devices. President Barack H. Obama’s administration has pledged reform.

Please join us for a Foley Executive Briefing Series program exploring tactics for expediting clearance and approval under the new FDA and other strategies for reducing time and cost to market. Panelists also will discuss how to improve your company’s ability to attract investment capital at higher valuations.

This informal, interactive panel session will be led by Martin D. Mann, Foley Emerging Technologies Partner, David L. Rosen, Foley Life Sciences Industry Team Co-Chair and FDA Regulatory Practice Leader, and Jon Lemelman, General Partner at Riverside Partners LLC.

Medical Devices: Reducing Time to Get New Products in the Market is part of the Foley Executive Briefing Series.